Visual summary
Establish laboratory surveillance, symptom reporting, and a shared response plan so recurrent injury is recognized promptly.
Text version
Two treatment priorities
Immune-mediated kidney injury must be addressed while considering the value of ongoing cancer therapy. Severity and diagnostic certainty shape the balance.
Grade with clinical context
Baseline kidney function, trajectory, urine findings, other organ toxicity, and hemodynamic factors matter alongside a creatinine-based grade.
Remove competing insults
Treat dehydration, infection, obstruction, and avoidable nephrotoxic exposure. Reconsider the diagnosis when the course is atypical.
Use supervised immunosuppression
Drug choice, intensity, duration, and taper require current guidance and specialist assessment. Monitor infection, glucose, and other treatment harms.
Rechallenge deliberately
Recovery, prior lesion, recurrence risk, cancer alternatives, and the patient's priorities inform whether to restart treatment. It is neither automatically safe nor automatically prohibited.
Plan follow-up before restarting
Establish laboratory surveillance, symptom reporting, and a shared response plan so recurrent injury is recognized promptly.
Continue learning
This graphic summarizes a topic. The full educational pages provide the broader discussion and references.